title: Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma.
abstract: Despite encouraging response rate of bevacizumab (BVZ) in recurrent glioblastoma, many patients do not respond to this schedule and most of the responders develop an early relapse. Plasma concentrations of VEGF, PlGF, Ang2, and sTie2 were assessed by ELISA before and during BVZ treatment in seventy patients. Baseline levels of VEGF-A, and PlGF were higher in patients than in healthy volunteers, whereas no difference was found for Ang2, and sTie2. No biomarker at baseline was associated with response, PFS or OS. At recurrence, the authors observed an increase of Ang2 suggesting that Ang2/sTie2 could be involved in the resistance to BVZ.
authors.affiliation: a Sorbonne Universités, Universite Pierre et Marie Curie , Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière , Paris , France.|b Institut National de la Santé et de la Recherche Médicale, U 1127 , Paris , France.|c Centre Nationale de la Recherche Scientifique, UMR 7225 , Paris , France.
authors.forename: Marianne
authors.initials: M
authors.lastname: Labussière
authors.affiliation: a Sorbonne Universités, Universite Pierre et Marie Curie , Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière , Paris , France.|b Institut National de la Santé et de la Recherche Médicale, U 1127 , Paris , France.|c Centre Nationale de la Recherche Scientifique, UMR 7225 , Paris , France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Cheneau
authors.affiliation: d Institut National de la Santé et de la Recherche Médicale, U 833 , Paris , France.|e Collège de France , Paris , France.
authors.forename: Claudia
authors.initials: C
authors.lastname: Prahst
authors.affiliation: f Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 , Paris , France.
authors.forename: Jaime
authors.initials: J
authors.lastname: Gállego Pérez-Larraya
authors.affiliation: f Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 , Paris , France.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Farina
authors.affiliation: f Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 , Paris , France.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lombardi
authors.affiliation: a Sorbonne Universités, Universite Pierre et Marie Curie , Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière , Paris , France.|b Institut National de la Santé et de la Recherche Médicale, U 1127 , Paris , France.|c Centre Nationale de la Recherche Scientifique, UMR 7225 , Paris , France.|g Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Neuropathologie R. Escourolle , Paris , France.|h OncoNeuroTek , Paris , France.
authors.forename: Karima
authors.initials: K
authors.lastname: Mokhtari
authors.affiliation: h OncoNeuroTek , Paris , France.
authors.forename: Amithys
authors.initials: A
authors.lastname: Rahimian
authors.affiliation: a Sorbonne Universités, Universite Pierre et Marie Curie , Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière , Paris , France.|b Institut National de la Santé et de la Recherche Médicale, U 1127 , Paris , France.|c Centre Nationale de la Recherche Scientifique, UMR 7225 , Paris , France.|f Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 , Paris , France.|h OncoNeuroTek , Paris , France.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Delattre
authors.affiliation: d Institut National de la Santé et de la Recherche Médicale, U 833 , Paris , France.|e Collège de France , Paris , France.
authors.forename: Anne
authors.initials: A
authors.lastname: Eichmann
authors.affiliation: a Sorbonne Universités, Universite Pierre et Marie Curie , Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière , Paris , France.|b Institut National de la Santé et de la Recherche Médicale, U 1127 , Paris , France.|c Centre Nationale de la Recherche Scientifique, UMR 7225 , Paris , France.|f Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2 , Paris , France.|h OncoNeuroTek , Paris , France.
authors.forename: Marc
authors.initials: M
authors.lastname: Sanson
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D042702:Angiopoietin-2 / Q000097:blood*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers; D016022:Case-Control Studies; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D005909:Glioblastoma / Q000097:blood* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000556:secondary; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000097:blood; D009364:Neoplasm Recurrence, Local; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D020533:Angiogenesis Inhibitors; D042702:Angiopoietin-2; D000970:Antineoplastic Agents; D015415:Biomarkers; D008565:Membrane Proteins; C098069:PIGF protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Ang2; Glioblastoma; bevacizumab; plasma biomarkers